Latest Breaking News On - Portuguese health authority - Page 1 : vimarsana.com

SOMAÍ Pharmaceuticals Receives EU-GMP Certification and Raises €5 million

Somai GMP Facility Somai GMP Facility LISBON, Portugal, Sept. 01, 2023 (GLOBE NEWSWIRE) SOMAÍ Pharmaceuticals Unipessoal LDA (the “Company” or “SOMAÍ”), the largest European pharmaceutical cannabis product manufacturer, is pleased to announce that it has received authorisation for its facility located in Lisbon, Portugal from the Portuguese Health Authority INFRAMED (authorisation number 42/V01 de 25/08/2023). This authorisation permits the Company to manufacture, import, and export medicinal

Nataliia garninaMichael sassanoAnton nakhodkinPharmaceuticals unipessoalPharmaceuticals ltdPortuguese health authorityBoard memberManaging directorGmp certificateThe companyCamp facilityGlobal marketsMedical cannabisDistribution channels

SOMAÍ Pharmaceuticals Receives EU-GMP Certification and

LISBON, Portugal, Sept. 01, 2023 (GLOBE NEWSWIRE) SOMAÍ Pharmaceuticals Unipessoal LDA (the “Company” or “SOMAÍ”), the largest European pharmaceutical.

Nataliia garninaAnton nakhodkinMichael sassanoPortuguese health authorityPharmaceuticals unipessoalPharmaceuticals ltdBoard memberManaging directorSomai pharmaceuticalsMedical cannabis

Somaí Pharmaceuticals Receives Eu-Gmp Certification And Raises €5 Million

Somaí Pharmaceuticals Receives Eu-Gmp Certification And Raises €5 Million
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Nataliia garninaMichael sassanoAnton nakhodkinPortuguese health authorityPharmaceuticals ltdPharmaceuticals unipessoalBoard memberManaging directorCannabis europe

From Manufacturing To Market: How This EU Pharma Co Fast-Tracked Cannabis Production

European pharmaceutical cannabis product manufacturer SOMAÍ Pharmaceuticals Unipessoal LDA received authorization for its facility in Lisbon, Portugal, from the Portuguese Health Authority INFRAMED. Why It Matters This authorization allows the company to produce, import, and export medicinal cannabis products to numerous global markets.

United statesAnton nakhodkinMichael sassanoPortuguese health authorityPharmaceuticals unipessoal

Cureus | SARS-CoV-2 Antibody Seroprevalence in Patients With Cancer on Systemic Antineoplastic Treatment in the First Wave of the COVID-19 Pandemic in Portugal

At the time of the first wave of the COVID-19 pandemic, patients with cancer were considered to be at high risk of serious illness and had a higher exposure risk since they needed frequent and nondeferrable hospital visits. Serological tests were not routinely used, and seroprevalence in this population was unknown. A single-center, cross-sectional study was developed to determine the seroprevalence of anti-SARS-CoV-2 antibodies (Abs) in patients with cancer undergoing systemic antineoplastic treatment. One hundred patients were consecutively recruited in a two-week period (6th-20th May 2020), and serum samples were tested for the presence of immunoglobulin M (IgM) and immunoglobulin G (IgG) Abs directed against both spike (S) and nucleocapsid (N) SARS-CoV-2 proteins in two distinct time points (at recruitment and 4-8 weeks later). IgG-positive results were subject to confirmation, in the same serum sample, using two distinct assays. At the time of the first study visit, no patient

United statesPortuguese health authorityPortuguese national health authorityHospital da luz lisboa ethics committeeEastern cooperative oncology groupLuz lisboa ethics committeeMedical oncology unitIgg absCov iggIgg abbott architectAbbott diagnosticsOncology unitLuz lisboaPerformance statusAbbott architectDay hospital